(ABL1), first identified as the BCR–ABL1 fusion protein in patients with Philadelphia chromosome-positive human leukemia, has been the target of successful chronic myeloid leukemia therapeutics28,29. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.